CRA International Reins in Experts to Boost Life Sciences
Leading consulting firm CRA International Inc. (CRAI) appointed multiple senior-level consultants to its Life Sciences Practice to support its strategy of bolstering skills in key focus areas including strategy and litigation consulting in Europe.
The firm appointed Ann Baker and Andrew Butcher, co-founders of life sciences consulting company Atkinson Cowan (now a part of CRA International), as Vice Presidents (:VP) in their Life Sciences Practice. The skilled professionals collaborate with pharmaceutical companies to provide strategic guidance and support the successful launch and marketing of new drugs. Their consulting services to research and development activities also include gaining stakeholder backing to support market access.
Ms. Baker specializes in strategy and business consulting and has vast experience in the pharmaceutical, medical devices and biotech sectors. On the other hand, Mr. Butcher’s proficiency lies in optimizing communications and reputation management to drive strategic efficiency.
Their exceptional integrated consulting approach, combined with the company’s established capabilities, enhances its service platform in London. The new additions also enhance the company’s scientific and clinical know-how in the Life Sciences segment.
Earlier this year, the firm hired Dr. Michael Mueller and Dr. Urs Wiedemann in Munich as VPs in the same segment. While Mueller specializes in strategic consulting, Wiedemann’s skills lie in portfolio management, appraisal of new technologies, and boosting sales and promotion.
Their elaborate scientific and clinical expertise strengthened and completed CRA International’s life sciences strategy consulting and transaction advisory services. Complementing the firm’s existing faculties, the talent addition enabled it to expand the footprint of its Life Sciences Practice globally.
CRA International’s Life Sciences segment is an important growth driver for the company, and the addition of such an experienced pool of consultants will enhance the capabilities and propel the segment’s growth, going forward.
CRA International presently holds a Zacks Rank #3 (Hold). Other companies in the consulting industry that warrant investor attention include CoreLogic, Inc. (CLGX), CBIZ, Inc. (CBZ) and FTI Consulting, Inc. (FCN), each sporting a Zacks Rank #1 (Strong Buy).
Leading consulting firm CRA International Inc. (CRAI) appointed multiple senior-level consultants to its Life Sciences Practice to support its strategy of bolstering skills in key focus areas including strategy and litigation consulting in Europe.
The firm appointed Ann Baker and Andrew Butcher, co-founders of life sciences consulting company Atkinson Cowan (now a part of CRA International), as Vice Presidents (:VP) in their Life Sciences Practice. The skilled professionals collaborate with pharmaceutical companies to provide strategic guidance and support the successful launch and marketing of new drugs. Their consulting services to research and development activities also include gaining stakeholder backing to support market access.
Ms. Baker specializes in strategy and business consulting and has vast experience in the pharmaceutical, medical devices and biotech sectors. On the other hand, Mr. Butcher’s proficiency lies in optimizing communications and reputation management to drive strategic efficiency.
Their exceptional integrated consulting approach, combined with the company’s established capabilities, enhances its service platform in London. The new additions also enhance the company’s scientific and clinical know-how in the Life Sciences segment.
Earlier this year, the firm hired Dr. Michael Mueller and Dr. Urs Wiedemann in Munich as VPs in the same segment. While Mueller specializes in strategic consulting, Wiedemann’s skills lie in portfolio management, appraisal of new technologies, and boosting sales and promotion.
Their elaborate scientific and clinical expertise strengthened and completed CRA International’s life sciences strategy consulting and transaction advisory services. Complementing the firm’s existing faculties, the talent addition enabled it to expand the footprint of its Life Sciences Practice globally.
CRA International’s Life Sciences segment is an important growth driver for the company, and the addition of such an experienced pool of consultants will enhance the capabilities and propel the segment’s growth, going forward.
CRA International presently holds a Zacks Rank #3 (Hold). Other companies in the consulting industry that warrant investor attention include CoreLogic, Inc. (CLGX), CBIZ, Inc. (CBZ) and FTI Consulting, Inc. (FCN), each sporting a Zacks Rank #1 (Strong Buy).
Read the Full Research Report on CRAI
Read the Full Research Report on FCN
Read the Full Research Report on CLGX
Read the Full Research Report on CBZ
Zacks Investment Research